

IMAGES IN PAEDIATRICS

Behind neurofibromatosis type 1: an unusual finding

Detrás de la neurofibromatosis tipo 1: un hallazgo inusual

Mariana Gouveia Lopes*, Margarida Maria Videira Henriques

Centro Hospitalar de Leiria, Leiria, Portugal

Received 19 January 2023; accepted 28 April 2023

Available online 17 August 2023



We present the case of a girl aged 9 months referred for evaluation of café-au-lait spots present from birth with progressive increase in their number.

She exhibited normal psychomotor development at the time of evaluation, meeting Sheridan's norms for age, with good weight gain and linear growth. There was no reported history of similar spots in family members.

The physical examination revealed the presence of more than 10 café-au-lait spots more than 5 mm in diameter. There were no ephelides. She had slightly raised, yellowish lesions measuring less than 1 cm on the scalp and back and asymmetry of the left lower extremity with pronounced bowing (Fig. 1). The plain radiograph evinced cortical thickening and narrowing of the medullary canal thinning, suggestive of tibial dysplasia with congenital pseudarthrosis (Fig. 2).

Genetic testing detected a heterozygous pathogenic variant, c.7486C>T p.(Arg2496Ter), in the *NF1* gene, with an autosomal dominant pattern of inheritance.



Figure 1 Left lower extremity asymmetry with pronounced bowing.

DOI of original article: <https://doi.org/10.1016/j.anpedi.2023.04.012>

* Corresponding author.

E-mail address: mariana.lopes@chleiria.min-saude.pt (M.G. Lopes).




Figure 2 Cortical thickening and narrowing of the medullary canal suggestive of tibial dysplasia with congenital pseudarthrosis.

Despite not having parents with known disease, she met the criteria for diagnosis of neurofibromatosis (NF).^{1,2}

We ought to highlight the rarity of a finding such as tibial dysplasia and pseudarthrosis, which only occurs in about 5% of children with a diagnosis of NF type 1.² These children are at higher risk of bone fracture.²

It is important to guarantee a multidisciplinary follow-up and access to appropriate treatment for these patients.³

References

1. Legius E, Messiaen L, Wolkenstein P, Pancza P, Avery RA, Berman Y, et al. Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. *Genet Med.* 2021;23:1506–13, <http://dx.doi.org/10.1038/s41436-021-01170-5>.
2. Kehrer-Sawatzki H, Cooper DN. Challenges in the diagnosis of neurofibromatosis type 1 (NF1) in young children facilitated by means of revised diagnostic criteria including genetic testing for pathogenic NF1 gene variants. *Human Genet.* 2022;141:177–91, <http://dx.doi.org/10.1007/s00439-021-02410-z>.
3. Miller DT, Freedenberg D, Schorry E, Ullrich NJ, Viskochil D, Korf BR. Health supervision for children with neurofibromatosis type 1. *Pediatrics.* 2019;143(5):e20190660, <http://dx.doi.org/10.1542/peds.2019-0660>.